Compare Capri Holdings Ltd (CPRI) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Capri Holdings Ltd vs Moderna, Inc. — how do they compare? Capri Holdings Ltd trades at $14.95 (market cap $1.67B), while Moderna, Inc. trades at $225 (market cap $78.65B). The key difference: Moderna, Inc. is far larger — about 47.1× Capri Holdings Ltd's market cap, and Moderna, Inc. is trading nearer its 52-week high, Capri Holdings Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Capri Holdings Ltd for 41 Days and Moderna, Inc. for 59 Days on average.
| CPRI | MRNA | |
|---|---|---|
Market Cap | $1.67B | $78.65B |
Volume | 3,722,279 | 37,373,437 |
Sector | Consumer Cyclical | Health |
52-Week High | $27.66 | $225.00 |
52-Week Low | $12.71 | $22.36 |
Typical Hold Time | 41 Days | 59 Days |
Enterprise Value | $2.95B | $74.80B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CPRI trades at $14.68, up 1.66% today, with a bullish technical signal from moving averages. The stock shows strong earnings beats recently but faces fundamental headwinds with a net loss of $1.18 billion in 2025 and declining revenue. Analyst consensus is a buy with a $20.57 price target, though sentiment is mixed due to Michael Kors brand challenges. Recent news highlights brand revitalization efforts and second-half growth expectations.
The outlook is cautiously optimistic given low valuation multiples and earnings beats, but significant risks include persistent revenue declines, high debt, and execution risks in the brand turnaround. The stock offers potential upside if operational improvements materialize, but investors must weigh turnaround progress against financial volatility.
Moderna (MRNA) trades at $197.00, up 0.26% today, reflecting a strong 2026 rally. The stock is technically bullish, with moving averages signaling strength and key support at $194. Fundamentally, revenue has declined from pandemic peaks to $1.92 billion in 2025, with net losses widening to -$2.82 billion, though recent quarters have beaten EPS estimates. The company's inclusion in the Nasdaq-100 index effective October 9, 2026, adds a positive catalyst. Analyst sentiment is mixed, with a consensus price target of $115.70 but a high target of $245.00, indicating divergent views on valuation after the stock's significant run-up.
The outlook for Moderna hinges on its pipeline beyond COVID-19, particularly cancer vaccines, but high valuation ratios (P/S of 35.08) and persistent losses pose risks. Upside potential exists if new products gain traction, yet investors face volatility from clinical trial outcomes and competitive pressures. The stock's proximity to 52-week highs suggests caution amid profit-taking signals from some analysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Capri Holdings Ltd
Michael Kors, Versace, and Jimmy Choo are the brands of Capri Holdings, a marketer, distributor, and retailer of upscale accessories and apparel. Kors, Capri's largest brand, offers handbags, footwear, and apparel through more than 800 company-owned stores, wholesale, and e-commerce. Versace (acquired in 2018) is known for its ready-to-wear luxury fashion, while Jimmy Choo (acquired in 2017) is best known for women's luxury footwear. John Idol has served as CEO since 2003.
Read more on CPRI →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
